Stocks and Investing
Stocks and Investing
Thu, March 29, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, March 28, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Etzer Darout Maintained (ACRS) at Buy with Decreased Target to $52 on, Mar 28th, 2018
Etzer Darout of Leerink Swann, Maintained "Aclaris Therapeutics, Inc." (ACRS) at Buy with Decreased Target from $54 to $52 on, Mar 28th, 2018.
Etzer has made no other calls on ACRS in the last 4 months.
There is 1 other peer that has a rating on ACRS. Out of the 1 peers that are also analyzing ACRS, 0 agree with Etzer's Rating of Hold.
This is the rating of the analyst that currently disagrees with Etzer
- Seamus Fernandez of "Leerink Swann" Maintained at Buy with Decreased Target to $54 on, Tuesday, March 13th, 2018
Contributing Sources